Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | RAB9A | P51151 | 3/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 8/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2072430 | 0.88 | KDM4E (0.67) | KDM4EALDH1A1RAB9ATDP1HPGD | |
| SCHEMBL3370261 | 0.84 | KDM4E (0.97) | KDM4EALDH1A1RAB9ATDP1HPGD | |
| SCHEMBL201951 | 0.84 | KDM4E (0.70) | KDM4EALDH1A1RAB9ATDP1HPGD | |
| SCHEMBL21032810 | 0.82 | KDM4E (1.00) | KDM4EALDH1A1RAB9ATDP1HPGD | |
| SCHEMBL10965297 | 0.82 | KDM4E (0.80) | KDM4EALDH1A1RAB9ATDP1HPGD | |
| SCHEMBL28317941 | 0.82 | MAPT (0.73) | KDM4EALDH1A1RAB9ATDP1HPGD | |
| SCHEMBL15762204 | 0.81 | ALDH1A1 (0.54) | KDM4EALDH1A1RAB9ATDP1HPGD | |
| SCHEMBL5717700 | 0.81 | KDM4E (0.78) | KDM4EALDH1A1RAB9ATDP1HPGD | |
| SCHEMBL7532002 | 0.80 | KDM4E (0.74) | KDM4EALDH1A1RAB9ATDP1HPGD | |
| SCHEMBL4774884 | 0.80 | SHMT2 (0.61) | KDM4EALDH1A1RAB9ATDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2023-08-03 | — | — | US | disclosed |
| CN-111848545-B | 1- (2- (4-methoxyphenyl) thiazole-4-yl) ethylamine and synthetic method thereof | 南通大学 | 2022-08-12 | — | — | CN | disclosed |
| CN-110218218-B | Benzofuran derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-03 | — | — | US | disclosed |
| CN-111848545-A | 1- (2- (4-methoxyphenyl) thiazole-4-yl) ethylamine and synthetic method thereof | 南通大学 | 2020-10-30 | — | — | CN | disclosed |
| US-20200123160-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2020-04-23 | — | — | US | disclosed |
| EP-3632919-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | Bristol-Myers Squibb Company (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3243826-B1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2019-10-30 | — | — | EP | disclosed |
| US-10428077-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-01 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| EP-1996180-B1 | BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD (GB) | 2011-08-03 | — | — | EP | disclosed |
| EP-1996180-B1 | BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD (GB) | 2011-08-03 | — | — | EP | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| EP-1996180-A1 | ANTIBACTERIAL AGENTS | Prolysis Limited (GB) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428077-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, TMPRSS4, F2R | KDM4E 3170/4885ALDH1A1 2559/4885RAB9A 2902/4885 |
| US-20200123160-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, TMPRSS4, F2R | KDM4E 3170/4885ALDH1A1 2559/4885RAB9A 2902/4885 |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | KDM4E 3172/4885ALDH1A1 2611/4885RAB9A 2789/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | KDM4E 2407/4885ALDH1A1 800/4885RAB9A 2799/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | KDM4E 2407/4885ALDH1A1 800/4885RAB9A 2799/4885 |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, TMPRSS4, F2R | KDM4E 3170/4885ALDH1A1 2559/4885RAB9A 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.